Do analysts recommend ENGN or VIRI?

enGene currently has a consensus target price of $12.68, indicating a potential upside of 682.83%. Given enGene's stronger consensus rating and higher probable upside, research analysts plainly believe enGene is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ENGN or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.25 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is ENGN or VIRI more profitable?

enGene's return on equity of -55.83% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Virios Therapeutics N/A -130.33% -115.00%

Do analysts rate VIRI or CGTX?

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 175.48%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, VIRI or CGTX?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A

Is VIRI or CGTX more profitable?

Cognition Therapeutics' return on equity of -72.68% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Cognition Therapeutics N/A -72.68% -53.07%

Do analysts rate PYXS or VIRI?

Pyxis Oncology currently has a consensus target price of $6.83, suggesting a potential upside of 288.26%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Pyxis Oncology is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PYXS or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Virios Therapeutics N/A -130.33% -115.00%

Do analysts rate COYA or VIRI?

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BDTX or VIRI more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Virios Therapeutics N/A -130.33% -115.00%

Virios Therapeutics (VIRI) Competitors

$1.54 -0.03 (-1.91%)

As of 06/12/2026

Compare

VIRI vs. ENGN, CGTX, PYXS, COYA, and BDTX

Should you buy Virios Therapeutics stock or one of its competitors? MarketBeat compares Virios Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virios Therapeutics include enGene (ENGN), Cognition Therapeutics (CGTX), Pyxis Oncology (PYXS), Coya Therapeutics (COYA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Virios Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

enGene has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

64.2% of enGene shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Virios Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, enGene had 11 more articles in the media than Virios Therapeutics. MarketBeat recorded 11 mentions for enGene and 0 mentions for Virios Therapeutics. enGene's average media sentiment score of 0.08 beat Virios Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Overall Sentiment
enGene	Neutral
Virios Therapeutics	Neutral

enGene currently has a consensus target price of $12.68, indicating a potential upside of 682.83%. Given enGene's stronger consensus rating and higher probable upside, research analysts plainly believe enGene is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

enGene's return on equity of -55.83% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

enGene beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Cognition Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 175.48%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cognition Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Cognition Therapeutics and 0 mentions for Virios Therapeutics. Cognition Therapeutics' average media sentiment score of 0.94 beat Virios Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Cognition Therapeutics	Positive

Cognition Therapeutics' return on equity of -72.68% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Cognition Therapeutics	N/A	-72.68%	-53.07%

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Summary

Cognition Therapeutics beats Virios Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Virios Therapeutics' return on equity of -130.33% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Virios Therapeutics	N/A	-130.33%	-115.00%

Pyxis Oncology currently has a consensus target price of $6.83, suggesting a potential upside of 288.26%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Pyxis Oncology is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Virios Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Virios Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.04	-$79.62M	-$1.31	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Pyxis Oncology had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 0 mentions for Virios Therapeutics. Pyxis Oncology's average media sentiment score of 1.68 beat Virios Therapeutics' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Very Positive
Virios Therapeutics	Neutral

Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Pyxis Oncology beats Virios Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Virios Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.99	-$21.23M	-$1.15	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Coya Therapeutics had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Coya Therapeutics and 0 mentions for Virios Therapeutics. Coya Therapeutics' average media sentiment score of 0.27 beat Virios Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Neutral
Virios Therapeutics	Neutral

Virios Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Virios Therapeutics	N/A	-130.33%	-115.00%

Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Coya Therapeutics beats Virios Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Black Diamond Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 471.43%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Black Diamond Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for Virios Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Virios Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
Virios Therapeutics	Neutral

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Black Diamond Therapeutics' return on equity of -30.18% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Virios Therapeutics	N/A	-130.33%	-115.00%

Black Diamond Therapeutics has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.43	$22.37M	-$0.77	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Black Diamond Therapeutics beats Virios Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.66M	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-5.70	1.45	24.00	24.42
Price / Sales	N/A	120.49	514.65	112.54
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	7.70	7.85	10.69	6.82
Net Income	-$5.30M	-$4.88M	$3.57B	$337.56M
7 Day Performance	2.67%	0.64%	0.61%	1.16%
1 Month Performance	-22.22%	-0.16%	1.56%	3.16%
1 Year Performance	-66.88%	47.51%	25.44%	30.60%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.54 -1.9%	N/A	-66.9%	$29.66M	N/A	N/A	5	Gap Up
ENGN enGene	3.7226 of 5 stars	$1.67 +1.2%	$12.68 +659.4%	-51.4%	$110.53M	N/A	N/A	31
CGTX Cognition Therapeutics	4.0571 of 5 stars	$1.15 -5.0%	$3.33 +189.9%	+305.6%	$108.29M	N/A	N/A	20	Positive News Gap Down
PYXS Pyxis Oncology	3.6502 of 5 stars	$1.70 +0.6%	$6.83 +302.0%	+46.7%	$107.07M	$13.86M	N/A	60	Gap Up
COYA Coya Therapeutics	2.7886 of 5 stars	$4.48 -1.5%	$15.33 +242.3%	-15.8%	$106.73M	$7.95M	N/A	6	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. ENGN, CGTX, PYXS, COYA, and BDTX

How does Virios Therapeutics compare to enGene?

Summary

How does Virios Therapeutics compare to Cognition Therapeutics?

Summary

How does Virios Therapeutics compare to Pyxis Oncology?

Summary

How does Virios Therapeutics compare to Coya Therapeutics?

Summary

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. ENGN, CGTX, PYXS, COYA, and BDTX

How does Virios Therapeutics compare to enGene?

Which has more risk and volatility, ENGN or VIRI?

Do insiders & institutionals believe in ENGN or VIRI?

Which has higher earnings and valuation, ENGN or VIRI?

Does the media prefer ENGN or VIRI?

Do analysts recommend ENGN or VIRI?

Is ENGN or VIRI more profitable?

Summary

How does Virios Therapeutics compare to Cognition Therapeutics?

Do analysts rate VIRI or CGTX?

Does the media refer more to VIRI or CGTX?

Is VIRI or CGTX more profitable?

Do insiders and institutionals believe in VIRI or CGTX?

Which has preferable valuation & earnings, VIRI or CGTX?

Which has more volatility & risk, VIRI or CGTX?

Summary

How does Virios Therapeutics compare to Pyxis Oncology?

Is PYXS or VIRI more profitable?

Do analysts rate PYXS or VIRI?

Do institutionals & insiders believe in PYXS or VIRI?

Which has stronger earnings and valuation, PYXS or VIRI?

Does the media prefer PYXS or VIRI?

Which has more volatility and risk, PYXS or VIRI?

Summary

How does Virios Therapeutics compare to Coya Therapeutics?

Which has better valuation and earnings, COYA or VIRI?

Do institutionals and insiders believe in COYA or VIRI?

Do analysts rate COYA or VIRI?

Does the media prefer COYA or VIRI?

Is COYA or VIRI more profitable?

Which has more risk & volatility, COYA or VIRI?

Summary

How does Virios Therapeutics compare to Black Diamond Therapeutics?

Do analysts rate BDTX or VIRI?

Which has more risk and volatility, BDTX or VIRI?

Does the media prefer BDTX or VIRI?

Do insiders and institutionals believe in BDTX or VIRI?

Is BDTX or VIRI more profitable?

Which has higher earnings & valuation, BDTX or VIRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools